Clinical Trial Update: Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg) [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study of Naproxen delayed-release tablets (375 mg) sponsored by Sandoz has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• Naproxen Delayed-Release Tablets 375 mg (naproxen)

Snippet

Sponsor: Sandoz | Conditions: Rheumatoid Arthritis, Osteoarthritis | Phase 1 | Status: COMPLETED